Goldman Sachs
VIVO

Goldman Sachs’s Meridian Bioscience Inc VIVO Stock Holding History

Goldman Sachs’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,056,680
Closed -$35.1M – 6470
2022
Q4 		$35.1M Buy
1,056,680
+83,046
+9% +$2.67M 0.01% 1460
2022
Q3 		$30.7M Buy
973,634
+745,570
+327% +$24.1M 0.01% 1501
2022
Q2 		$6.94M Buy
228,064
+18,656
+9% +$505K ﹤0.01% 2839
2022
Q1 		$5.44M Sell
209,408
-9,547
-4% -$227K ﹤0.01% 3278
2021
Q4 		$4.47M Sell
218,955
-7,049
-3% -$135K ﹤0.01% 3531
2021
Q3 		$4.35M Buy
226,004
+9,643
+4% +$192K ﹤0.01% 3478
2021
Q2 		$4.8M Sell
216,361
-159,765
-42% -$3.39M ﹤0.01% 3374
2021
Q1 		$9.87M Sell
376,126
-24,147
-6% -$574K ﹤0.01% 2578
2020
Q4 		$7.48M Buy
400,273
+16,689
+4% +$312K ﹤0.01% 2682
2020
Q3 		$6.51M Buy
383,584
+172,492
+82% +$3.35M ﹤0.01% 2701
2020
Q2 		$4.92M Buy
211,092
+50,510
+31% +$732K ﹤0.01% 2812
2020
Q1 		$1.35M Sell
160,582
-105,477
-40% -$888K ﹤0.01% 3555
2019
Q4 		$2.6M Sell
266,059
-350,581
-57% -$3.29M ﹤0.01% 3464
2019
Q3 		$5.85M Buy
616,640
+118,894
+24% +$1.25M ﹤0.01% 2732
2019
Q2 		$5.91M Buy
497,746
+74,698
+18% +$900K ﹤0.01% 2734
2019
Q1 		$7.45M Buy
423,048
+177,792
+72% +$2.96M ﹤0.01% 2664
2018
Q4 		$4.26M Buy
245,256
+44,863
+22% +$765K ﹤0.01% 3027
2018
Q3 		$2.99M Sell
200,393
-58,713
-23% -$910K ﹤0.01% 3322
2018
Q2 		$4.12M Buy
259,106
+63,024
+32% +$940K ﹤0.01% 3088
2018
Q1 		$2.78M Buy
196,082
+45,591
+30% +$675K ﹤0.01% 3345
2017
Q4 		$2.11M Sell
150,491
-58,275
-28% -$853K ﹤0.01% 3762
2017
Q3 		$2.98M Buy
208,766
+72,080
+53% +$1.03M ﹤0.01% 3628
2017
Q2 		$2.15M Buy
136,686
+3,915
+3% +$56.4K ﹤0.01% 3775
2017
Q1 		$1.83M Sell
132,771
-30,813
-19% -$431K ﹤0.01% 3835
2016
Q4 		$2.9M Buy
163,584
+27,448
+20% +$482K ﹤0.01% 3510
2016
Q3 		$2.63M Buy
136,136
+70,591
+108% +$1.38M ﹤0.01% 3598
2016
Q2 		$1.28M Buy
65,545
+27,591
+73% +$541K ﹤0.01% 3991
2016
Q1 		$782K Sell
37,954
-91,048
-71% -$1.79M ﹤0.01% 4309
2015
Q4 		$2.65M Sell
129,002
-19,447
-13% -$373K ﹤0.01% 3392
2015
Q3 		$2.54M Buy
148,449
+5,368
+4% +$98.1K ﹤0.01% 3557
2015
Q2 		$2.67M Sell
143,081
-19,599
-12% -$363K ﹤0.01% 3553
2015
Q1 		$3.1M Buy
162,680
+83,427
+105% +$1.54M ﹤0.01% 3358
2014
Q4 		$1.3M Sell
79,253
-32,564
-29% -$559K ﹤0.01% 4276
2014
Q3 		$1.98M Buy
111,817
+8,850
+9% +$174K ﹤0.01% 3940
2014
Q2 		$2.13M Buy
102,967
+15,482
+18% +$318K ﹤0.01% 3929
2014
Q1 		$1.91M Sell
87,485
-112,432
-56% -$2.58M ﹤0.01% 4004
2013
Q4 		$5.3M Buy
199,917
+17,379
+10% +$427K ﹤0.01% 3018
2013
Q3 		$4.31M Buy
182,538
+38,663
+27% +$903K ﹤0.01% 3100
2013
Q2 		$3.09M Buy
+143,875
New +$3.1M ﹤0.01% 3245

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's VIVO Position: Q1 2023 in Review

Goldman Sachs sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 1,056,680 shares — an estimated $35.1M sold.

Goldman Sachs first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $35.1M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Goldman Sachs reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 1,056,680 Meridian Bioscience Inc shares in Q1 2023, an estimated $35.1M.
  • Goldman Sachs first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Goldman Sachs's Meridian Bioscience Inc position peaked at $35.1M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.